Cargando…

Real World Data in Health Technology Assessment of Complex Health Technologies

The available evidence on relative effectiveness and risks of new health technologies is often limited at the time of health technology assessment (HTA). Additionally, a wide variety in real-world data (RWD) policies exist among HTA organizations. This study assessed which challenges, related to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hogervorst, Milou A., Pontén, Johan, Vreman, Rick A., Mantel-Teeuwisse, Aukje K., Goettsch, Wim G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866967/ https://www.ncbi.nlm.nih.gov/pubmed/35222045 http://dx.doi.org/10.3389/fphar.2022.837302

Ejemplares similares

Synergy between health technology assessments and clinical guidelines for multiple sclerosis
por: Hogervorst, Milou A., et al.
Publicado: (2023)

Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
por: Hogervorst, Milou A, et al.
Publicado: (2023)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
por: Vreman, Rick A., et al.
Publicado: (2020)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs
por: Callenbach, Marcelien H. E., et al.
Publicado: (2022)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
por: Vreman, Rick A., et al.
Publicado: (2020)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision‐making of oncology medicines
por: Kalf, Rachel R. J., et al.
Publicado: (2021)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
por: Wang, Ting, et al.
Publicado: (2020)

Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study
por: Ogar, Comfort K., et al.
Publicado: (2023)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

Nutrition and health technology assessment: when two worlds meet
por: Poley, Marten J.
Publicado: (2015)

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study
por: Postma, Doerine J., et al.
Publicado: (2018)

Administrative Data Linkage in Brazil: Potentials for Health Technology Assessment
por: Ali, M Sanni, et al.
Publicado: (2019)

Availability, prices and affordability of UN Commission’s lifesaving medicines for reproductive and maternal health in Uganda
por: Kibira, Denis, et al.
Publicado: (2017)

Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
por: Willemen, Marjolein J., et al.
Publicado: (2011)

Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
por: Kusynová, Zuzana, et al.
Publicado: (2022)

Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa
por: Narsai, Kirti, et al.
Publicado: (2012)

Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies
por: Jakovljevic, Mihajlo, et al.
Publicado: (2017)

Delayed payment schemes in Central-Eastern Europe and Middle-East
por: Ádám, Ildikó, et al.
Publicado: (2022)

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
por: Polak, Tobias B, et al.
Publicado: (2022)

Approach to machine learning for extraction of real-world data variables from electronic health records
por: Adamson, Blythe, et al.
Publicado: (2023)

Getting the Right Evidence After Drug Approval
por: Vreman, Rick A., et al.
Publicado: (2020)

The Life Cycle of Health Technologies. Challenges and Ways Forward
por: Gutiérrez-Ibarluzea, Iñaki, et al.
Publicado: (2017)

Conceptual Framework of the Impact of Health Technology on Healthcare System
por: Farid, Samar F.
Publicado: (2019)

Integration of real-world evidence from different data sources in health technology assessment
por: Graili, Pooyeh, et al.
Publicado: (2023)

Missing data on accessibility of children’s medicines
por: Joosse, Iris R, et al.
Publicado: (2022)

Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia
por: Sagwa, Evans L, et al.
Publicado: (2016)

Institutionalizing health technology assessment in Egypt: Situational analysis and roadmap
por: Pinilla-Dominguez, Pilar, et al.
Publicado: (2022)

Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study
por: Sagwa, Evans L, et al.
Publicado: (2014)

Transferability of real-world data across borders for regulatory and health technology assessment decision-making
por: Jaksa, Ashley, et al.
Publicado: (2022)

Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia
por: Kibira, Denis, et al.
Publicado: (2021)

Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion
por: Iskrov, Georgi, et al.
Publicado: (2016)

Editorial: Big Data, Pharmacogenomics and Real-World Research in Pharmacology
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

Drug utilization research in Peru: Is real-world data available?
por: Rodríguez-Tanta, L. Yesenia, et al.
Publicado: (2023)

Editorial: New Horizons in Health-Promoting Technologies: From Development to Rational Use
por: Lopes, Luciane Cruz, et al.
Publicado: (2020)

Editorial: The inaugural Monash international health science and technology conference: pharmacology perspectives
por: Khaw, Kooi Yeong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ag8i0rpiurrpfg1idb13ho6tej